Assessment of addiction severity among ritual users of ayahuasca
This paper reports the results of two survey-based studies (n=242), comparing the addiction severity among rural ayahuasca users with those in urban areas. Overall, the authors report that ritual ayahuasca use doesn't appear to be associated with deleterious psychosocial effects typically associated with other drugs of abuse.
Authors
- Jordi Riba
- Maria Barbanoj
- Paulo Barbosa
Published
Abstract
Ayahuasca is a psychoactive beverage used for magico-religious purposes in the Amazon. Recently, Brazilian syncretic churches have helped spread the ritual use of ayahuasca abroad. This trend has raised concerns that regular use of this N,N-dimethyltryptamine-containing tea may lead to the medical and psychosocial problems typically associated with drugs of abuse. Here we assess potential drug abuse-related problems in regular ayahuasca users. Addiction severity was assessed using the Addiction Severity Index (ASI), and history of alcohol and illicit drug use was recorded. In Study 1, jungle-based ayahuasca users (n = 56) were compared vs. rural controls (n = 56). In Study 2, urban-based ayahuasca users (n = 71) were compared vs. urban controls (n = 59). Follow-up studies were conducted 1 year later. In both studies, ayahuasca users showed significantly lower scores than controls on the ASI Alcohol Use, and Psychiatric Status subscales. The jungle-based ayahuasca users showed a significantly higher frequency of previous illicit drug use but this had ceased at the time of examination, except for cannabis. At follow-up, abstinence from illicit drug use was maintained in both groups except for cannabis in Study 1. However, differences on ASI scores were still significant in the jungle-based group but not in the urban group. Despite continuing ayahuasca use, a time-dependent worsening was only observed in one subscale (Family/Social relationships) in Study 2. Overall, the ritual use of ayahuasca, as assessed with the ASI in currently active users, does not appear to be associated with the deleterious psychosocial effects typically caused by other drugs of abuse.
Research Summary of 'Assessment of addiction severity among ritual users of ayahuasca'
Introduction
Ayahuasca is a psychoactive plant tea traditionally used in Amazonian indigenous medicine and magico-religious rituals. It is typically prepared from Banisteriopsis caapi, which provides reversible monoamine oxidase inhibitors (MAOIs), and Psychotria viridis, which contains the hallucinogen N,N-dimethyltryptamine (DMT). In recent decades Brazilian syncretic churches that employ ayahuasca in organised rituals have expanded internationally, prompting legal scrutiny because DMT is a controlled substance. Neurobiological distinctions between ayahuasca and classical drugs of abuse — notably predominant serotonergic actions of DMT versus the dopaminergic activation commonly implicated in addiction — plus ethnographic observations, raise questions about the beverage's abuse potential and its long-term psychosocial effects. Fábregas and colleagues designed two longitudinal, community-based comparative studies to assess addiction-related medical and psychosocial problems in regular ritual ayahuasca users. Using the Brazilian Portuguese version of the Addiction Severity Index (ASI) and a structured history of alcohol and illicit drug use, the investigators compared jungle-based and urban-based ayahuasca users with matched non-user control groups, with assessments at baseline and again about one year later. The primary objective was to determine whether continued ritual use of ayahuasca is associated with the types of deleterious outcomes typically seen with substances of abuse.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Authors
- APA Citation
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010). Assessment of addiction severity among ritual users of ayahuasca. Drug and Alcohol Dependence, 111(3), 257-261. https://doi.org/10.1016/j.drugalcdep.2010.03.024
References (7)
Papers cited by this study that are also in Blossom
da Silveira, D. X., Doering-Silveira, E., Grob, C. S. et al. · Journal of Psychoactive Drugs (2005)
Doering-Silveira, E., Lopez, E., Grob, C. S. et al. · Journal of Psychoactive Drugs (2005)
Gable, R. S. · Addiction (2006)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
McKenna, D. · ACS Chemical Neuroscience (2004)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Cited By (82)
Papers in Blossom that reference this study
Aicher, H. D., Wicki, I. A., Meling, D. et al. · Journal of Psychopharmacology (2025)
Agin-Liebes, G. I., Nielson, E. M., Zingman, M. et al. · Psychology of Addictive Behaviors (2024)
Aicher, H. D., Mueller, M. J., Dornbierer, D. A. et al. · Frontiers in Psychiatry (2024)
Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Chenhall, R., Sarris, J., Bouso, J. C. et al. · Psychoactives (2023)
Zafar, R., Siegel, M., Harding, R. et al. · Frontiers in Psychiatry (2023)
Galvão-Coelho, N. L., De Meiroz Grilo, M. L. P., de Sousa, G. M. et al. · Frontiers in Behavioural Neuroscience (2022)
Perkins, D., Pagni, B. A., Sarris, J. et al. · Frontiers in Pharmacology (2022)
Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)
Show all 82 papersShow fewer
Johnson, M. W. · Current Topics in Behavioral Neurosciences (2022)
Kohek, M., Ona, G., Dos Santos, R. G. et al. · Journal of Psychoactive Drugs (2022)
Rodriguez, L., Lopez, A., Moyna, G. et al. · ACS Omega (2022)
Maia, L. O., Massarentti, C. M., Tófoli, L.F. · Psychopharmacology (2022)
Argento, E., Socias, M. E., Hayashi, K. et al. · International Journal of Drug Policy (2022)
Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)
Nichols, C. D., Wiatr, K., Figiel, M. et al. · Journal of Neurochemistry (2021)
Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
Perkins, D., Opaleye, E. S., Simonová, H. et al. · Drug and Alcohol Review (2021)
Ruffell, S. G. D., Netzband, N., Tsang, W. et al. · Frontiers in Psychiatry (2021)
Cox, D. J., Garcia-Romeu, A., Johnson, M. W. · The American Journal of Drug and Alcohol Abuse (2021)
Rush, B., Marcus, O., García, S. et al. · Frontiers in Pharmacology (2021)
González, D., Cantillo, J., Perez, I. et al. · Frontiers in Pharmacology (2021)
Rodrigues, L. S., Rossi, G. N., Rocha, J. M. et al. · European Archives of Psychiatry and Clinical Neuroscience (2021)
Nigam, K. B., Pandurangi, A. K. · SN Comprehensive Clinical Medicine (2021)
O'shaughnessy, D. M., Berlowitz, I., Rodd, R. et al. · Therapeutic Advances in Psychopharmacology (2021)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Netzband, N., Ruffell, S., Linton, &. S. et al. · Psychopharmacology (2020)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Argento, E., Capler, R., Thomas, G. et al. · Drug and Alcohol Review (2019)
da Silva, F. S., Galvão-Coelho, N. L. · brazilian Journal of Psychiatry (2019)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Ona, G., Kohek, M., Massaguer, T. et al. · Journal of Psychoactive Drugs (2019)
Mello, S. M., Soubhia, P. C., Silveira, G. et al. · Journal of Psychoactive Drugs (2018)
Domínguez-Clavé, E., Soler, J., Pascual, J. C. et al. · Psychopharmacology (2018)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Berro, L. F., Marinho, E. A. V., Cata-Preta, E. G. et al. · Frontiers in Pharmacology (2018)
Sloshower, J. A. · Plant Medicines Healing and Psychedelic Science (2018)
Maqueda, A. E. · Plant Medicines Healing and Psychedelic Science (2018)
Barbosa, P., Tófoli, L.F., Bogenschutz, M. P. et al. · Frontiers in Psychiatry (2018)
Dorsen, C., Palamar, J., Shedlin, M. G. · Addiction Research and Theory (2018)
Elices, M., Soler, J., Domínguez-Clavé, E. et al. · Frontiers in Pharmacology (2018)
Adams, T. · Biorxiv (2018)
Barsuglia, J. P., Polanco, M., Palmer, R. et al. · Progress in Brain Research (2018)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Dakic, V., Nascimento, J. M., Sartore, R. C. et al. · Scientific Reports (2017)
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S. et al. · Scientific Reports (2017)
Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)
Apud, I., Romaní, O. · International Journal of Drug Policy (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)
Barbosa, P., Strassman, R. J., da Silveira, D. X. et al. · Comprehensive Psychiatry (2016)
Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C. et al. · Journal of Psychopharmacology (2016)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Tupper, K. W., Wood, E., Yensen, R. et al. · Canadian Medical Association Journal (2015)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2014)
Winkelman, M. J. · Current Drug Abuse Reviews (2014)
Loizaga-Velder, A., Verres, R. · Journal of Psychoactive Drugs (2014)
Winstock, A. R., Kaar, S., Borschmann, R. · Journal of Psychopharmacology (2013)
Schenberg, E. E. · Sage Open Medicine (2013)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Bogenschutz, M. P. · Current Drug Abuse Reviews (2013)
Dos Santos, R. G. · Journal of Psychoactive Drugs (2013)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Bogenschutz, M. P., Pommy, J. A. · Drug Testing and Analysis (2012)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.